n CME : Your SA Journal of CPD - AIDS overview

Volume 21, Issue 7
  • ISSN : 0256-2170



Extracted from text ... AIDS OVERVIEW 413 An interesting paper1 compares universal nevirapine (NVP) therapy, which is the provision of the drug without testing, with targeted NVP therapy for pregnant women known to be HIV-seropositive. It has been suggested that universal NVP is superior to targeted NVP in high-prevalence, resource-poor settings. The authors have suggested that the proportion of women who accept the strategy when it is offered may be higher for universal therapy, since a woman does not have to know her serostatus. However, they also suggest that adherence may be higher for targeted therapy since knowing HIV status could act ..

Loading full text...

Full text loading...


Article metrics loading...


This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error